The efficacy of PARP inhibitors beyond germline BRCA1/2 has been highlighted in a recent phase II study of talazoparib monotherapy which demonstrated activity in patients with germline PALB2 pathogenic variants45, while TBCRC 048 has shown activity of olaparib in breast cancers with somatic BRCA1/2 mutations46. This evidence concerns the gene PALB2 and breast carcinoma.